Concepedia

Author

Alan K. Matsumoto

Arthritis and Rheumatism Associates

Also Known As

A K Matsumoto, Alan K Matsumoto, Alan K. Matsumoto, Alan Matsumoto

22

Publications

1K

Citations

14

H-Index

19

Concepts

All Affiliations

Arthritis and Rheumatism AssociatesJohns Hopkins UniversityMetroplex Clinical Research CenterStanford UniversityAltoona Center for Clinical Research
AK

About

Alan K. Matsumoto is an author at Arthritis and Rheumatism Associates specializing in medicine, orthopaedics, and pain disorders.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

103

2

Orthopaedics

2

2

59

3

Health Sciences

1

1

32

4

Pathology

1

1

44

5

Pharmacology

1

1

32

Alan K. Matsumoto

×

15

Publications

982

Citations

13

H-Index

YearCitations

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Stanley Cohen, Mark C. Genovese, Ernest Choy,

Annals of the Rheumatic Diseases

2017

182

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

Alan K. Matsumoto, Augustin Melian, David R. Mandel,

PubMed

2002

135

Spirituality, well‐being, and quality of life in people with rheumatoid arthritis

Susan J. Bartlett, Ralph L. Piedmont, Andrew Bilderback,

Arthritis Care & Research

2003

123

Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial

Alan K. Matsumoto, Najib Babul, Harry Ahdieh

Pain Medicine

2005

118

Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six‐month, double‐blind, randomized, dose‐ranging study

Daniel E. Fürst, Kenneth G. Saag, Max Fleischmann,

Arthritis & Rheumatism

2002

113

T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides

Larry W. Moreland, Elizabeth E. Morgan, T. C. Adamson,

Arthritis & Rheumatism

1998

73

Resolution of gouty tophi after twelve weeks of pegloticase treatment

Herbert S. B. Baraf, Alan K. Matsumoto, Allan N. Maroli,

Arthritis & Rheumatism

2008

44

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Stanley Cohen, José L. Pablos, Karel Pavelká,

Arthritis Research & Therapy

2019

34

Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial

Alan Kivitz, Maria Greenwald, Stanley Cohen,

Journal of the American Geriatrics Society

2004

33

Pain management in osteoarthritis: A focus on onset of efficacy—a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials

Wendy P. Battisti, Nathaniel P. Katz, Arthur L. Weaver,

Journal of Pain

2004

32

Page 1